DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hwmmw6/colazal_and_giazo) has announced the addition of the "Colazal & Giazo (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Colazal is an aminosalicylate prodrug. This means that its active ingredient, balsalazide disodium, contains an azo bond that can only be processed by bacterial azo reductases in the colon. Following its metabolism by the colonic commensal bacteria, mesalamine is released into and is restricted to the colon area, preventing the active ingredient from being systemically absorbed. Giazo is an aminosalicylate prodrug. This means that its active ingredient, balsalazide disodium, contains an azo bond that can only be processed by bacterial azo reductases in the colon.
- Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Colazal & Giazo including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Colazal & Giazo for the top three countries from 2012 to 2022.
Sales information covered for the US, Italy, and the UK.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Colazal & Giazo (balsazide disodium)
For more information visit http://www.researchandmarkets.com/research/hwmmw6/colazal_and_giazo